JB Chemicals & Pharmaceuticals Limited

rs,

ironment. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company

70%

ord across multiple businesses 5 Pillar brands ranked in Top 300 IPM brands, contributing over 70% of domestic formulations revenues^ 40+ Regulated and semi-regulated markets of presence, throu

rs 3

regulatory bodies, such as US-FDA, EU-GMP, TGA-AUS, SAHPRA-S.A.; # Includes Medical Reps and Managers 3 World Class Manufacturing Facilities Seven state-of-the-art manufacturing facilities in Western In

19%

ncial Overview – Q4 & FY22: Revenue Overall JBCPL | FY22 Revenue (INR): 2,424 Cr | YoY Gr% (FY22): 19%  | YoY Gr% (Q4): 18%  Revenues (INR cr) 19% 2,424 2,043 528 18% 625 Q4 FY21 Q4 FY22 FY2

18%

FY22: Revenue Overall JBCPL | FY22 Revenue (INR): 2,424 Cr | YoY Gr% (FY22): 19%  | YoY Gr% (Q4): 18%  Revenues (INR cr) 19% 2,424 2,043 528 18% 625 Q4 FY21 Q4 FY22 FY21 FY22 27 8 85 Re

30%

Y  Domestic Formulations continued its market-beating performance • Q4 FY22 recorded growth of 30% • Retained the spot of the fastest growing among Top 30 companies in IPM^  International busine

9%

nessed double-digit growth across several segments • International business growth in Q4 FY22 of 9% YoY • Strong surge in Q4 driven by Contract Manufacturing, 218 892 South Africa and APIs * Inc

32%

22 despite market slowdown Domestic Formulations | FY22 Revenue (INR): 1,173 Cr | YoY Gr% (FY22): 32%  | YoY Gr% (Q4): 30%  Revenues (INR cr) 32% 1,173 892 30% 287 221 Q4 FY21 Q4 FY22 FY21

29%

growing company among the top 30 IPM companies in Q4 FY22 and MAT Mar’22 • MAT Mar’22: JB grew at 29% vs market growth of 18% • Q4 FY22: JB grew at 21% vs market growth of 10%  Key pillar brands cont

21%

Q4 FY22 and MAT Mar’22 • MAT Mar’22: JB grew at 29% vs market growth of 18% • Q4 FY22: JB grew at 21% vs market growth of 10%  Key pillar brands continue their market-beating performance and stand w

10%

• MAT Mar’22: JB grew at 29% vs market growth of 18% • Q4 FY22: JB grew at 21% vs market growth of 10%  Key pillar brands continue their market-beating performance and stand well above market growth

38%

M# Market-Beating growth* Leadership position in the covered markets 29% vs IPM growth of 18% 38% + market share in 5 molecule categories Position in IPM No. of brands in Top 300 IPM 25^ Rank

ISIN

1

ISIN

is one of the INE572A01028), established in 1976, fastest growing pharmaceutical companies in India and a leading player in the hypertension segment. Besides its strong India presence, which accounts for majority of its revenue, its other two home markets are Russia and South Africa. In India, the company has five brands among the top 300 IPM brands in the country. finished formulations to over 40 countries including the USA. Besides supplying branded generic formulations to several countries, in the manufacturing of medicated lozenges. The company ranks among the top 5 manufacturers globally in medicated and herbal lozenges. It has seven state of the art manufacturing facilities in India including a dedicated manufacturing facility for lozenges. The manufacturing facilities are certified by leading regulators across the world. is also a leader company exports The its it For more and Pharmaceuticals Limited, please visit www.jbcpl.com. Chemicals details J.B. on For further information,